

340B In Action

The 340B prescription drug program is a vital lifeline for safety-net providers, supporting critical health services in our communities. The program is narrowly tailored to reach only hospitals that provide a high level of services to low-income individuals or that serve isolated rural communities. Savings from the 340B program help hospitals meet the healthcare needs of underserved patients across the country. Congress should preserve and protect the 340B program as an essential part of the safety-net that does not rely on taxpayer dollars.

340B by the Numbers

150,000

residents in our primary service area

4

Average number of chronic diseases per patient in our Community Care Network



63%

of our hospital population served by Medicare or MediCal



1,400

employees serving patients in over 22 sites in El Dorado County

\$14 million*

The 2020 value of our 340B program helped fund vital community health services

\$55 million

Our uncompensated care includes charity care, bad debt, and underpayment

The 340B Impact in Our Community

As a not-for-profit hospital, we rely on our 340B savings to meet the needs of the low-income and rural patients we serve, including Medicare and MediCal beneficiaries.

EXAMPLES OF SERVICES FUNDED BY 340B INCLUDE:

- **Marshall CARES** - our Clinically Assisted Recovery and Education Services for patients who have substance use disorder, including opioid dependency;
- **Patient services beyond clinical care** including health education, transportation services, care coordination, in-home visits and other services to help keep our residents healthy;
- **Updates to technology and equipment** to ensure we are providing the highest quality care to those we serve;
- **The provision of charity care** and the acceptance of government pay programs that reimburse less than the cost of delivering the service (underpayment);
- **Our Community Care Network** provides hands-on care and case management to the most medically frail and vulnerable members of our community. This program is reducing hospitalizations and length of stays for these patients and improving their lives.

*340B savings are at risk due to unilateral restrictive actions of pharmaceutical manufacturers. Both the Trump and Biden administrations have supported 340B and opposed these actions.